Login / Signup

Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study.

Paolo GalloAntonio De VincentisFrancesca TerraccianiAndrea FalcomatàValeria Pace PalittiMaurizio RusselloAnthony VignoneDomenico AlvaroRaffaella TortoraAntonio GriecoMaurizio PompiliVincenza CalvarusoVeneziano MarziaMarco TizzaniAlessandro CanegliasFrancesco FrigoMarcantonio GesualdoAlfredo MarzanoValerio RosatoErnesto ClaarRosanna VillaniAntonio IzziRaffaele CozzolongoAntonio CozzolinoAldo AiroldiChiara MazzarelliMarco DistefanoClaudia IegriStefano FagiuoliVincenzo MessinaEnrico RagoneRodolfo SaccoPierluigi CacciatoreFlora MasuttiLory Saveria CrocèAlessandra MorettiValentina FlagielloGiulia Di PasqualeAntonio PicardiUmberto Vespasiani-Gentilucci
Published in: Journal of clinical medicine (2024)
Background and aims: Management of severe thrombocytopenia poses significant challenges in patients with chronic liver disease. Here, we aimed to evaluate the first real-world European post-marketing cohort of cirrhotic patients treated with lusutrombopag, a thrombopoietin receptor agonist, verifying the efficacy and safety of the drug. Methods: In the REAl-world Lusutrombopag treatment in ITalY (REALITY) study, we collected data from consecutive cirrhotic patients treated with lusutrombopag in 19 Italian hepatology centers, mostly joined to the "Club Epatologi Ospedalieri" (CLEO). Primary and secondary efficacy endpoints were the ability of lusutrombopag to avoid platelet transfusions and to raise the platelet count to ≥50,000/μL, respectively. Treatment-associated adverse events were also collected. Results: A total of 66 patients and 73 cycles of treatment were included in the study, since 5 patients received multiple doses of lusutrombopag over time for different invasive procedures. Fourteen patients (19%) had a history of portal vein thrombosis (PVT). Lusutrombopag determined a significant increase in platelet count [from 37,000 (33,000-44,000/μL) to 58,000 (49,000-82,000), p < 0.001]. The primary endpoint was met in 84% of patients and the secondary endpoint in 74% of patients. Baseline platelet count was the only independent factor associated with response in multivariate logistic regression analysis (OR for any 1000 uL of 1.13, CI95% 1.04-1.26, p 0.01), with a good discrimination power (AUROC: 0.78). Notably, a baseline platelet count ≤ 29,000/μL was identified as the threshold for identifying patients unlikely to respond to the drug (sensitivity of 91%). Finally, de novo PVT was observed in four patients (5%), none of whom had undergone repeated treatment, and no other safety or hemorrhagic events were recorded in the entire population analyzed. Conclusions: In this first European real-world series, lusutrombopag demonstrated efficacy and safety consistent with the results of registrational studies. According to our results, patients with baseline platelet counts ≤29,000/μL are unlikely to respond to the drug.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • pulmonary embolism
  • drug induced
  • big data
  • smoking cessation